Lakefront Biotherapeutics NV (LKFT) stock
LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.07−0.32 (-0.93%)
Close on Nov 18, 2026Market cap $2.25BP/E 6.3Yield –
Lakefront Biotherapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
For fiscal 2025 it was €320.88M, up 333.1% from the year before. The highest annual figure on record is €320.88M in fiscal 2025.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €320.88M | +333.1% |
| FY2024 | Dec 31, 2024 | €74.08M | -65.0% |
| FY2023 | Dec 31, 2023 | €211.70M | – |
| FY2022 | Dec 31, 2022 | -€217.99M | – |
| FY2021 | Dec 31, 2021 | -€103.23M | – |
| FY2020 | Dec 31, 2020 | -€305.44M | -303.8% |
| FY2019 | Dec 31, 2019 | €149.85M | – |
| FY2018 | Dec 31, 2018 | -€29.26M | – |
| FY2017 | Dec 31, 2017 | -€115.70M | -314.2% |
| FY2016 | Dec 31, 2016 | €54.01M | – |
| FY2015 | Dec 31, 2015 | -€118.41M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2021 | Jun 30, 2021 | -€64.33M | – |
| Q2 FY2020 | Jun 30, 2020 | -€115.04M | – |
| Q2 FY2019 | Jun 30, 2019 | -€47.25M | – |
| Q2 FY2018 | Jun 30, 2018 | -€21.77M | – |
| Q2 FY2017 | Jun 30, 2017 | -€35.64M | – |
See a number that looks wrong?